home / stock / opt / opt news

OPT News and Press, Opthea Limited From 10/26/21

Stock Information
Company Name: Opthea Limited
Stock Symbol: OPT
Market: NASDAQ
Website: opthea.com
Menu
OPT OPT Quote OPT Short OPT News OPT Articles OPT Message Board
Get OPT Alerts

News, Short Squeeze, Breakout and More Instantly...
OPT - Opthea Granted Chinese Patent Covering OPT-302

MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the grant of Chinese Patent Number (CN) 1064...
OPT - Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD

MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that the first clinical trial sites in the Asia-Pac...

OPT - Tracking Baker Brothers Portfolio - Q2 2021 Update

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

OPT - Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302

MELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that enrollment for its Phase 3 pivotal clinical pr...
OPT - Opthea To Present at September Investor Conferences

MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Of...

OPT - Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD) OPT-302 Granted FDA Fast Track Designation for Wet AMD Received FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD ShORe and COAST Phase 3 Clinical Tr...

OPT - ATI Physical Therapy: A Busted SPAC Presents A Compelling Opportunity

ATI Physical Therapy recently came public through a SPAC. The company recently revised revenue and earnings estimates down. The market has not reacted kindly and the stock has decreased to approximately 4 Dollars. Advent Private Equity owns 63% of the shares and an investor at...
OPT - Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference

MELBOURNE, Australia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Off...

OPT - Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that recruitment is open to patients in Canada for ...

OPT - Tracking Baker Brothers Portfolio - Q1 2021 Update

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Previous 10 Next 10